Effect of Pomegranate Extract (Punica Granatum L.) Supplementation in Arterial Pulmonary Hypertension in Children with Acyanotic Congenital Heart Disease

Phase 1

Recruiting

• Conditions: Pulmonary HypertensionAcyanotic Heart Disease; Pulmonary Hypertension; Acyanotic Heart DIsease; Pomegranate

• Registration Number: TCTR20221006005
• Lead Sponsor: /A

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-10-06
• Study Completion: 2022-10-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Inclusion criteria are patient age 1 month until 10 years, diagnosed with acyanotic heart disease left to right shunt, given standard lung hypertension treatment and the parent had signed informed consent.

Exclusion Criteria

Subjects were excluded if they had prior heart surgery, were planned to have surgery within 3 months, had chronic parenchymal lung disease, had chromosomal or other disease preventing normal development, had infection or renal impairment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pulmonary Arterial Pressure 3 months Echocardiography

Secondary Outcome Measures

Name	Time	Method
T pro BNP and ADMA 3 months Laboratory,Functional Pulmonary Arterial Pressure 3 months PVRI Pediatric functional classification